Across the quiet ledger of human habit, a morning cup has long been a companion to labor, conversation, and small rituals of rest. Now a study of nearly half a million people in the UK Biobank suggests that this familiar drink may also stand in a protective relation to the liver, the body's tireless chemical workshop, with lower rates of chronic liver disease and of death from it among those who drank it. The observers who tracked these lives for about a decade were careful to note that they have witnessed a pattern rather than a cause, and that the people they followed were mostly white and c
Coffee Linked to Lower Chronic Liver Disease Risk, Peaking at Three to Four Cups a Day
The benefit peaked at three to four cups a day.
Mark
Start with the headline figure. Coffee drinkers had a 49 percent lower risk of dying from chronic liver disease. That's big.
Mimi
It is, and it sits alongside a 21 percent lower risk of developing the disease at all. The pattern held for caffeinated and decaffeinated coffee, which is interesting in itself.
Luke
Worth saying plainly, though: this is observational. It shows an association. It doesn't show coffee caused the lower risk.
Mark
And the cups? Three to four a day is where the benefit peaked.
Mimi
Yes, and ground coffee showed the strongest effect. It's high in kahweol and cafestol, which have helped against liver disease in animal studies.
Luke
Animal studies, note. The study doesn't show those compounds are doing the work in people. Instant coffee is low in both and still showed a smaller benefit, so the explanation isn't settled.
Mark
Why does the lead author emphasise lower-income countries?
Mimi
Dr Kennedy points out coffee is widely accessible, and the burden of chronic liver disease is highest where healthcare access is worst. He frames it as a potential preventative treatment.
Luke
But the participants were mostly white and from higher socio-economic backgrounds. So whether it holds in those very countries is unknown.
Mark
Anything else the reader should hold loosely?
Luke
Coffee intake was recorded once, at enrolment. Over 10.7 years people's habits could easily have changed, and the study can't capture that.
Mimi
Which is why the authors want tighter control of consumption and more diverse groups next.
El Pulso
- A study of nearly 500,000 people has raised the possibility that an everyday habit could shield the liver from a serious disease.
- Coffee drinkers showed a 21 percent lower risk of chronic liver disease and a 49 percent lower risk of dying from it compared with non-drinkers.
- The protective effect peaked at three to four cups a day, with ground coffee appearing to offer the strongest benefit.
- Researchers are urging caution, since the findings are observational, coffee was recorded only once, and the cohort was largely white and higher-income.
- The team hopes larger, more diverse trials will test whether coffee can become a low-cost preventive measure, especially in lower-income countries.
Across the quiet ledger of human habit, a morning cup has long been a companion to labor, conversation, and small rituals of rest. Now a study of nearly half a million people in the UK Biobank suggests that this familiar drink may also stand in a protective relation to the liver, the body's tireless chemical workshop, with lower rates of chronic liver disease and of death from it among those who drank it. The observers who tracked these lives for about a decade were careful to note that they have witnessed a pattern rather than a cause, and that the people they followed were mostly white and comfortably placed, leaving open how far such a pattern travels. Still, the study offers a hopeful thought: that an everyday, widely available habit might one day be part of how people protect themselves from a disease that falls hardest where care is scarcest.
The study drew on 495,585 participants in the UK Biobank, whose coffee habits were recorded when they joined and who were then followed for a median of 10.7 years. About 78 percent of them drank coffee, whether ground or instant, caffeinated or decaffeinated, while the rest drank none. Researchers from the Universities of Southampton and Edinburgh found that drinkers fared better on several liver measures, with lower risks of chronic liver disease and of fatty liver disease, and a markedly lower risk of dying from liver disease.
The benefit was strongest for people who drank ground coffee, which is rich in the compounds kahweol and cafestol, both shown in animal studies to protect against liver disease. Instant coffee, lower in those compounds, also showed a smaller association, suggesting other ingredients may play a part. The lead author, Dr Oliver Kennedy, said that coffee's wide availability could make it a valuable preventive option, particularly in lower-income countries where the disease burden is highest and healthcare is hardest to reach.
The researchers were clear about the study's limits. Coffee intake was measured only once, at enrolment, and the participants were predominantly white and from higher socio-economic backgrounds, so the results may not transfer easily to other populations. The work shows an association rather than proof that coffee reduces risk. Future research, the authors say, should control coffee consumption more rigorously and test the findings in more diverse groups.
The numbers come from a very large group of people: 495,585 participants in the UK Biobank, whose coffee habits were recorded when they enrolled and who were then followed for a median of 10.7 years. Of those, 78 percent, or 384,818 people, drank coffee of some kind, whether ground or instant, caffeinated or decaffeinated. The other 22 percent, 109,767 people, drank none.
Researchers at the Universities of Southampton and Edinburgh compared the two groups and found that coffee drinkers fared better on several liver measures. Compared with people who did not drink coffee, drinkers had a 21 percent lower risk of chronic liver disease and a 20 percent lower risk of chronic or fatty liver disease. Their risk of dying from chronic liver disease was 49 percent lower. The association was present for both caffeinated and decaffeinated coffee, and it peaked at three to four cups a day.
During the follow-up there were 3,600 cases of chronic liver disease, 301 of them fatal. There were also 5,439 cases of chronic liver disease or steatosis, the build-up of fat in the liver also known as fatty liver disease, and 184 cases of hepatocellular carcinoma, a type of liver cancer.
The type of coffee mattered. The largest benefit appeared among people who drank ground coffee, which contains high levels of kahweol and cafestol. Both compounds have been shown in animal studies to be beneficial against chronic liver disease. Instant coffee, which is low in those two compounds, was also linked to reduced risk, though by a smaller margin than ground. The study suggests that this could point to other ingredients, or a combination of them, playing a role.
Dr Oliver Kennedy, the lead author, said coffee is widely accessible and that the findings may mean it could offer a potential preventative treatment for chronic liver disease. He said that would be especially valuable in lower-income countries with worse access to healthcare, where the burden of the disease is highest.
The researchers set out clear limits. Coffee consumption was reported only once, at enrolment, so the study cannot account for changes in how much or what kind of coffee people drank over the 10.7 years. The participants were predominantly white and from higher socio-economic backgrounds, which may make the findings hard to generalise to other countries and populations. The work is observational, showing an association rather than proving that coffee itself lowers risk.
The authors say future research could test the relationship with more rigorous control over how much coffee is consumed, and that the findings should be validated in more diverse groups of participants. The study is published in the journal BMC Public Health.
Citas Notables
Coffee is widely accessible, and the benefits seen may mean it could offer a potential preventative treatment for chronic liver disease, especially in lower-income countries.— Dr Oliver Kennedy, lead author (paraphrased)
Quieres la nota completa?
Lee el original en TheJournal.ie ↗
Science & Space